PN-477 (Oral)
Obesity & Co-morbidities
IND-EnablingPhase 1 initiation 2H '26
Key Facts
Indication
Obesity & Co-morbidities
Phase
IND-Enabling
Status
Phase 1 initiation 2H '26
Company
About Protagonist Therapeutics
Protagonist Therapeutics is a leader in peptide-based drug discovery, leveraging its proprietary Vectrix™ platform to overcome historical challenges of oral bioavailability and stability. The company has achieved significant milestones, including the FDA approval of icotrokinra for psoriasis and a pending NDA for rusfertide in polycythemia vera. Its strategy combines internal development of wholly-owned assets with strategic partnerships, like the one with Janssen for icotrokinra, to build a diversified, multi-indication portfolio.
View full company profileTherapeutic Areas
Other Obesity & Co-morbidities Drugs
| Drug | Company | Phase |
|---|---|---|
| PN-477 (SC) | Protagonist Therapeutics | IND-Enabling |